Literature DB >> 25301451

Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway.

Yan Shao1, Chung Mau Lo1, Chang Chun Ling1, Xiao Bing Liu1, Kevin Tak-Pan Ng1, Andrew Chi Yuen Chu1, Yuen Yuen Ma1, Chang Xian Li1, Sheung Tat Fan1, Kwan Man2.   

Abstract

Human hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide with a poor prognosis of limited survival. The role of regulatory B cell (Breg), a new important B cell subset, in HCC progression remains unclear. We firstly found that the percentage of B cells at tumor margin was significantly higher than that in tumor and non-tumor regions. Especially, increased intrahepatic B cells at tumor margin were positively associated with tumor invasive features and more tumor recurrence. Besides, HCC patients had a significantly higher percentage of circulating Bregs than healthy people. Increased circulating Bregs were correlated with advanced tumor staging, tumor multiplicity and venous infiltration. Next, we firstly revealed that human Bregs promoted HCC tumor growth independent of Tregs in SCID mice. The migration of Bregs from blood into tumor was also confirmed in mice. Finally, we further explored the molecular mechanism of Bregs promoting proliferation and migration of HCC cells in vitro. Bregs promoted HCC growth and invasiveness by directly interacting with liver cancer cells through the CD40/CD154 signaling pathway.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bregs; HCC; Invasion

Mesh:

Substances:

Year:  2014        PMID: 25301451     DOI: 10.1016/j.canlet.2014.09.026

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  42 in total

Review 1.  B cells, plasma cells and antibody repertoires in the tumour microenvironment.

Authors:  George V Sharonov; Ekaterina O Serebrovskaya; Diana V Yuzhakova; Olga V Britanova; Dmitriy M Chudakov
Journal:  Nat Rev Immunol       Date:  2020-01-27       Impact factor: 53.106

Review 2.  The role of regulatory B cells in digestive system diseases.

Authors:  Zhenyu Zhou; Lei Gong; Xiaoyun Wang; Zhen Hu; Gaojue Wu; Xuejun Tang; Xiaobin Peng; Shuan Tang; Miao Meng; Hui Feng
Journal:  Inflamm Res       Date:  2016-11-22       Impact factor: 4.575

3.  Phenotypic and functional characteristics of CD39high human regulatory B cells (Breg).

Authors:  F Figueiró; L Muller; S Funk; E K Jackson; A M O Battastini; T L Whiteside
Journal:  Oncoimmunology       Date:  2016-02-26       Impact factor: 8.110

Review 4.  [B cells in head and neck oncology].

Authors:  P J Schuler; C Brunner; T K Hoffmann
Journal:  HNO       Date:  2018-04       Impact factor: 1.284

5.  IL-21/anti-Tim1/CD40 ligand promotes B10 activity in vitro and alleviates bone loss in experimental periodontitis in vivo.

Authors:  Yang Hu; Pei Yu; Xinbo Yu; Xingxue Hu; Toshihisa Kawai; Xiaozhe Han
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-06-03       Impact factor: 5.187

6.  Macrophage regulation of B cell proliferation.

Authors:  Naomi Goldman; Kornelija Valiuskyte; Jennifer Londregan; Adam Swider; John Somerville; James E Riggs
Journal:  Cell Immunol       Date:  2017-02-21       Impact factor: 4.868

Review 7.  Progress and Prospects of Non-Canonical NF-κB Signaling Pathway in the Regulation of Liver Diseases.

Authors:  Li Tao; Xiaomeng Ren; Wenhui Zhai; Zheng Chen
Journal:  Molecules       Date:  2022-07-02       Impact factor: 4.927

8.  IgAλ monoclonal gammopathy of undetermined significance (MGUS) associated with primary selective IgM deficiency.

Authors:  Sudhir Gupta; Sudhanshu Agrawal
Journal:  Am J Clin Exp Immunol       Date:  2019-08-15

Review 9.  Noncoding RNA-mediated macrophage and cancer cell crosstalk in hepatocellular carcinoma.

Authors:  Zhixia Zhou; Zhan Wang; Jie Gao; Zhijuan Lin; Yin Wang; Peipei Shan; Mengkun Li; Tingting Zhou; Peifeng Li
Journal:  Mol Ther Oncolytics       Date:  2022-03-16       Impact factor: 6.311

Review 10.  The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.

Authors:  Nicole J Flynn; Rajasekharan Somasundaram; Kimberly M Arnold; Jennifer Sims-Mourtada
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.